Results 51 to 60 of about 1,394 (181)

Corrigendum: Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences. [PDF]

Drugs Context
Bernardo Rossini, Nicola Cecchi, Felice Clemente, Maria Rosaria De Paolis, Stefan Hohaus, Vanessa Innao, Mariano Lucignano, Roberto Massaiu, Giovanna Palumbo, Gian Matteo Rigolin, Francesca Gaia Rossi, Luisa Verga, Attilio Guarini   +12 more
europepmc   +3 more sources

Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy

Xiehe Yixue Zazhi, 2023
Castleman disease (CD) is a group of rare and heterogenous hematological diseases included in the 'Rare disease catalogue' of China. Among the different clinical subtypes of CD, idiopathic multicentric Castleman disease (iMCD) is characterized by ...
ZHANG Lu, LI Jian
doaj   +1 more source

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease

Haematologica, 2022
Castleman disease is a polyclonal lymphoproliferative disorder characterized by unicentric or multicentric lymphadenopathy with characteristic histomorphological features, in addition to variable inflammatory symptomatology. The molecular mechanisms and
Pedro Horna, Rebecca L. King, Dragan Jevremovic, David C. Fajgenbaum, Angela Dispenzieri   +4 more
doaj   +1 more source

Idiopathic Multicentric Castleman Disease

Journal of Oncology Research Review & Reports, 2021
Castleman Disease (CD) is a spectrum of heterogenous hematological diseases that share characteristic clinical, histopathological, and immunological features. We present a case of a 61-y female with history of non-Hodgkin Lymphoma and hypothyroidism presenting with fatigue, generalized weakness, nausea, and poor appetite.
openaire   +1 more source

TAFRO syndrome: A case report and review of the literature

Human Pathology: Case Reports, 2017
TAFRO syndrome is a rare clinicopathologic variant of idiopathic multicentric Castleman disease characterized by Thrombocytopenia, Ascites (anasarca), myeloFibrosis, Renal dysfunction, and Organomegaly.
Tieying Hou, Jaspreet Dhillon, Wenbin Xiao, Elaine S. Jaffe, Amy M. Sands, Vishala Neppalli, George Deeb, Nan Zhang   +7 more
doaj   +1 more source

Rapid Relapse of Idiopathic Multicentric Castleman Disease After Siltuximab Discontinuation in a Case with Complete Remission for More Than 10 Years [PDF]

Turk J Haematol
Gao YH, Li J, Zhang L.
europepmc   +2 more sources

TAFRO Syndrome Mimicking Solid Cancer and Successfully Treated by Tocilizumab: A Case and Literature Review

Journal of Cancer Research and Practice, 2023
TAFRO syndrome, or now formally termed idiopathic multicentric Castleman disease (iMCD) with thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly (iMCD-TAFRO), describes a unique subtype of iMCD.
Pei-An Fu, Chia-Chi Wu, Ya-Ting Hsu
doaj   +1 more source

How we manage idiopathic multicentric Castleman disease.

Clinical advances in hematology & oncology : H&O, 2022
Joshua D. Brandstadter, David C. Fajgenbaum   +1 more
openalex   +3 more sources

Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine

Vaccines, 2022
Idiopathic Multicentric Castleman Disease (iMCD) is a potentially life-threatening systemic disease whose complex symptomatology is due to cytokine dysregulation.
Christian Hoffmann, Thomas Wechselberger, Heinz Drexel, Susanne Dertinger, Stefan Dirnhofer, Sheila K. Pierson, David C. Fajgenbaum, Andreas Kessler   +7 more
doaj   +1 more source

Idiopathic Multicentric Castleman Disease with Strikingly Elevated IgG4 Concentration in the Serum and Abundant IgG4-Positive Cells in the Tissue: A Case Report

Diagnostics, 2022
Idiopathic multicentric Castleman disease (iMCD) can be challenging to distinguish clinically and histopathologically from Immunoglobulin G4-related disease (IgG4RD).
Chia-Chun Cheng, Ying-Chu Chen, Yung-Hsiang Hsu, Kuei-Ying Su   +3 more
doaj   +1 more source